UY35617A - Inhibidores de la fosfatidilinositol 3-quinasa - Google Patents
Inhibidores de la fosfatidilinositol 3-quinasaInfo
- Publication number
- UY35617A UY35617A UY0001035617A UY35617A UY35617A UY 35617 A UY35617 A UY 35617A UY 0001035617 A UY0001035617 A UY 0001035617A UY 35617 A UY35617 A UY 35617A UY 35617 A UY35617 A UY 35617A
- Authority
- UY
- Uruguay
- Prior art keywords
- inhibitors
- phosfatidylinositol
- quinasa
- pi3k
- pi3kd
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Inhibidores de fosfatidilinositol 3-quinasa (PI3K) de fórmula (I),o sales o isómeros farmacéuticamente aceptables de los mismos, en donde n, m, R1, R2, R4, y R3 son como se definen en la presente. Estos compuestos son de utilidad para el tratamiento de condiciones mediadas por una o más isoformas de PI3K, tal como PI3Kd. La presente divulgación provee además composiciones farmacéuticas que incluyen un compuesto de fórmula (I), o sales farmacéuticamente aceptables del mismo, y métodos para usar estos compuestos y composiciones para el tratamiento de condiciones mediadas por una o más isoformas de PI3K, tal como PI3Kd.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361835333P | 2013-06-14 | 2013-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35617A true UY35617A (es) | 2014-12-31 |
Family
ID=51177160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035617A UY35617A (es) | 2013-06-14 | 2014-06-16 | Inhibidores de la fosfatidilinositol 3-quinasa |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9221795B2 (es) |
| EP (1) | EP3008053B1 (es) |
| JP (1) | JP6030783B2 (es) |
| KR (1) | KR101709436B1 (es) |
| CN (1) | CN105308034B (es) |
| AR (1) | AR096621A1 (es) |
| AU (2) | AU2014277950B2 (es) |
| BR (1) | BR112015031475A2 (es) |
| CA (1) | CA2915129C (es) |
| EA (1) | EA028319B1 (es) |
| ES (1) | ES2667173T3 (es) |
| HK (2) | HK1220968A1 (es) |
| IL (1) | IL242677B (es) |
| MX (1) | MX347988B (es) |
| NO (1) | NO2994608T3 (es) |
| NZ (1) | NZ714710A (es) |
| PL (1) | PL3008053T3 (es) |
| PT (1) | PT3008053T (es) |
| SG (1) | SG11201509910YA (es) |
| SI (1) | SI3008053T1 (es) |
| TR (1) | TR201806822T4 (es) |
| TW (1) | TWI644909B (es) |
| UY (1) | UY35617A (es) |
| WO (1) | WO2014201409A1 (es) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| NZ717410A (en) | 2008-01-04 | 2017-07-28 | Intellikine Llc | Heterocyclic containing entities, compositions and methods |
| CN103002738A (zh) | 2010-05-21 | 2013-03-27 | 英特利凯恩有限责任公司 | 用于激酶调节的化学化合物、组合物和方法 |
| AR084824A1 (es) | 2011-01-10 | 2013-06-26 | Intellikine Inc | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas |
| EP2751093A1 (en) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| SI3008053T1 (en) * | 2013-06-14 | 2018-06-29 | Gilead Calistoga Llc | PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS |
| CA2920059A1 (en) | 2013-09-22 | 2015-03-26 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| NZ726360A (en) | 2014-06-13 | 2018-04-27 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
| EA201692267A1 (ru) | 2014-06-13 | 2017-06-30 | Джилид Сайэнс, Инк. | Ингибиторы фосфатидилинозитол-3-киназы |
| KR20170015508A (ko) | 2014-06-13 | 2017-02-08 | 길리애드 사이언시즈, 인코포레이티드 | 포스파티딜이노시톨 3-키나제 억제제로서의 퀴나졸리논 유도체 |
| SG11201610095SA (en) | 2014-06-13 | 2016-12-29 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
| EP3164400A1 (en) | 2014-07-04 | 2017-05-10 | Lupin Limited | Quinolizinone derivatives as pi3k inhibitors |
| US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| GB201506786D0 (en) * | 2015-04-21 | 2015-06-03 | Ucb Biopharma Sprl | Therapeutic use |
| EP3317277B1 (en) | 2015-07-01 | 2021-01-20 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| WO2017059224A2 (en) | 2015-10-01 | 2017-04-06 | Gilead Sciences, Inc. | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers |
| JP2019500368A (ja) | 2015-12-17 | 2019-01-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔａｎｋ結合キナーゼ阻害剤化合物 |
| JP2019510752A (ja) | 2016-03-04 | 2019-04-18 | ギリアード サイエンシーズ， インコーポレイテッド | オートタキシン阻害剤の組成物及び合剤 |
| US10792283B2 (en) | 2016-03-05 | 2020-10-06 | Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. | Quinoline analogs as phosphatidylinositol 3-kinase inhibitors |
| EP3440113A1 (en) | 2016-04-08 | 2019-02-13 | Gilead Sciences, Inc. | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
| US10059769B2 (en) | 2016-06-13 | 2018-08-28 | I-Mab | Anti-PD-L1 antibodies and uses thereof |
| US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| EP3493797A1 (en) | 2016-08-04 | 2019-06-12 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
| TW201815787A (zh) * | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| CN108017641B (zh) * | 2016-11-02 | 2021-01-05 | 深圳铂立健医药有限公司 | 吡唑并嘧啶化合物作为pi3k抑制剂及其应用 |
| WO2018085069A1 (en) | 2016-11-03 | 2018-05-11 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
| US20180141939A1 (en) | 2016-11-22 | 2018-05-24 | Gilead Sciences, Inc. | Solid forms of a bet inhibitor |
| HUE058975T2 (hu) | 2017-01-24 | 2022-09-28 | I Mab Biopharma Us Ltd | CD73-ellenes antitestek és alkalmazásaik |
| AU2018224136B2 (en) | 2017-02-24 | 2021-10-21 | Gilead Sciences, Inc. | Inhibitors of Bruton's Tyrosine Kinase |
| US10314844B2 (en) | 2017-02-24 | 2019-06-11 | Gilead Sciences, Inc. | Inhibitors of Bruton's tyrosine kinase |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| EP3658560A4 (en) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | SOMATOSTAT IN MODULATORS AND USES THEREOF |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| US10751339B2 (en) | 2018-01-20 | 2020-08-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
| KR102445054B1 (ko) | 2018-02-13 | 2022-09-22 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US10442799B1 (en) | 2018-04-07 | 2019-10-15 | Fuqiang Ruan | Heterocyclic compounds and uses thereof |
| JP7242702B2 (ja) | 2018-04-19 | 2023-03-20 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| WO2019217780A1 (en) | 2018-05-11 | 2019-11-14 | Phosphorex, Inc. | Microparticles and nanoparticles having negative surface charges |
| KR20240074001A (ko) | 2018-05-14 | 2024-05-27 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 억제제 |
| BR112020026746A2 (pt) | 2018-07-13 | 2021-03-30 | Gilead Sciences, Inc. | Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição. |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| EP3870566A1 (en) | 2018-10-24 | 2021-09-01 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| CA3129022C (en) | 2019-03-07 | 2023-08-01 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
| AU2020315598A1 (en) | 2019-07-16 | 2022-03-03 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| BR112022005687A2 (pt) | 2019-09-30 | 2022-06-21 | Gilead Sciences Inc | Vacinas contra o hbv e métodos para tratar o hbv |
| PL4045083T3 (pl) | 2019-10-18 | 2024-05-13 | Forty Seven, Inc. | Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej |
| MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CR20220303A (es) | 2019-12-24 | 2022-09-02 | Gilead Sciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
| PE20231067A1 (es) | 2020-02-14 | 2023-07-17 | Jounce Therapeutics Inc | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos |
| US12110294B2 (en) | 2020-05-01 | 2024-10-08 | Gilead Sciences, Inc. | CD73 compounds |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| AU2022297373A1 (en) | 2021-06-23 | 2024-01-04 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US11999733B2 (en) | 2021-06-23 | 2024-06-04 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| CN118139858A (zh) | 2021-10-28 | 2024-06-04 | 吉利德科学公司 | 吡地嗪-3(2h)-酮衍生物 |
| EP4422756A1 (en) | 2021-10-29 | 2024-09-04 | Gilead Sciences, Inc. | Cd73 compounds |
| US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| KR20240125012A (ko) | 2021-12-22 | 2024-08-19 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| DK4245756T3 (da) | 2022-03-17 | 2024-10-21 | Gilead Sciences Inc | Ikaros zinkfinger-familiens nedbrydere og anvendelse heraf |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| IL316058A (en) | 2022-04-21 | 2024-11-01 | Gilead Sciences Inc | Compounds modulate KRAS G12D |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4965288A (en) | 1988-02-25 | 1990-10-23 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5059714A (en) | 1988-02-25 | 1991-10-22 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5021456A (en) | 1988-02-25 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5182297A (en) | 1988-02-25 | 1993-01-26 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US5252608A (en) | 1988-02-25 | 1993-10-12 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4943593A (en) | 1988-02-25 | 1990-07-24 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5120764A (en) | 1988-11-01 | 1992-06-09 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of lysyl oxidase |
| US4997854A (en) | 1989-08-25 | 1991-03-05 | Trustees Of Boston University | Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates |
| GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
| US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
| DE69831446T2 (de) | 1997-06-09 | 2006-06-14 | Pfizer Prod Inc | Chinazolin-4-on AMPA Antagonisten |
| ATE286033T1 (de) | 1999-09-16 | 2005-01-15 | Curis Inc | Vermittler von igel signalwegen, deren zusammenstellungen und verwendungen |
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| AU774748B2 (en) | 1999-10-27 | 2004-07-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| ATE502941T1 (de) * | 2000-04-25 | 2011-04-15 | Icos Corp | Hemmer der menschlichen phosphatidyl-inositol-3- kinase delta |
| FR2828206B1 (fr) | 2001-08-03 | 2004-09-24 | Centre Nat Rech Scient | Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire |
| AU2003228283A1 (en) | 2002-03-07 | 2003-09-22 | X-Ceptor Therapeutics, Inc. | Quinazolinone modulators of nuclear receptors |
| WO2004037176A2 (en) | 2002-10-21 | 2004-05-06 | Bristol-Myers Squibb Company | Quinazolinones and derivatives thereof as factor xa inhibitors |
| CN1886384A (zh) | 2003-11-25 | 2006-12-27 | 希龙公司 | 喹唑酮化合物作为抗癌药剂 |
| WO2005113556A1 (en) | 2004-05-13 | 2005-12-01 | Icos Corporation | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
| WO2005123696A1 (en) | 2004-06-15 | 2005-12-29 | Astrazeneca Ab | Substituted quinazolones as anti-cancer agents |
| US7939538B2 (en) | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
| DE102005024017A1 (de) | 2005-05-25 | 2006-11-30 | Merck Patent Gmbh | Chinazolinone |
| CA2680853C (en) | 2007-03-23 | 2012-07-17 | Amgen Inc. | 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| US20110217300A1 (en) | 2007-06-22 | 2011-09-08 | Arqule, Inc. | Quinazolinone Compounds and Methods of Use Thereof |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| NZ717410A (en) | 2008-01-04 | 2017-07-28 | Intellikine Llc | Heterocyclic containing entities, compositions and methods |
| US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
| WO2010059593A1 (en) | 2008-11-18 | 2010-05-27 | Intellikine, Inc. | Methods and compositions for treatment of ophthalmic conditions |
| ES2598358T3 (es) | 2009-02-13 | 2017-01-27 | Ucb Pharma, S.A. | Derivados de quinolina como inhibidores de PI3K quinasa |
| CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| UY32743A (es) | 2009-06-25 | 2010-12-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| JP2012531435A (ja) | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | ＰＩ３Ｋ阻害剤としての４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オン誘導体 |
| KR20120063515A (ko) | 2009-09-09 | 2012-06-15 | 아빌라 테라퓨틱스, 인크. | Ｐｉ３ 키나제 억제제 및 이들의 용도 |
| ES2534096T3 (es) | 2009-11-12 | 2015-04-17 | Ucb Pharma, S.A. | Derivados de piridina y pirazina bicíclicos condensados como inhibidores de quinasa |
| WO2011075699A2 (en) | 2009-12-18 | 2011-06-23 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| WO2011075628A1 (en) | 2009-12-18 | 2011-06-23 | Amgen Inc. | Heterocyclic compounds and their uses |
| UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| CN103002738A (zh) * | 2010-05-21 | 2013-03-27 | 英特利凯恩有限责任公司 | 用于激酶调节的化学化合物、组合物和方法 |
| NZ705135A (en) | 2010-05-26 | 2017-10-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
| US20130085131A1 (en) | 2010-07-01 | 2013-04-04 | Amgen Inc. | Heterocyclic compounds and their uses |
| WO2012003271A1 (en) | 2010-07-02 | 2012-01-05 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
| ES2693257T3 (es) | 2010-09-14 | 2018-12-10 | Exelixis, Inc. | Inhibidores de PI3K-delta y métodos para su uso y fabricación |
| WO2012054332A1 (en) | 2010-10-18 | 2012-04-26 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| US20140031355A1 (en) | 2010-11-04 | 2014-01-30 | Amgen Inc. | Heterocyclic compounds and their uses |
| AU2011326427B2 (en) | 2010-11-10 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| MX2013005567A (es) | 2010-11-17 | 2013-10-30 | Amgen Inc | Derivados de quinolina como inhibidores de pik3. |
| US20130267526A1 (en) | 2010-12-23 | 2013-10-10 | Amgen, Inc. | Heterocyclic compounds and their uses |
| AR084824A1 (es) | 2011-01-10 | 2013-06-26 | Intellikine Inc | Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas |
| KR20130116358A (ko) | 2011-02-09 | 2013-10-23 | 에프. 호프만-라 로슈 아게 | Pi3 키나아제 억제제로서 헤테로사이클릭 화합물 |
| WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
| WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
| EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
| EP2518070A1 (en) * | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| EP2751093A1 (en) * | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9202145B2 (en) | 2012-11-30 | 2015-12-01 | Safety Management Services, Inc. | System and method of determining material reaction or sensitivity using high-speed video frames |
| US9029384B2 (en) | 2012-12-21 | 2015-05-12 | Gilead Calistoga, LLC. | Phosphatidylinositol 3-kinase inhibitors |
| US9018221B2 (en) | 2012-12-21 | 2015-04-28 | Gilead Calistoga, Llc | Phosphatidylinositol 3-kinase inhibitors |
| SI3008053T1 (en) * | 2013-06-14 | 2018-06-29 | Gilead Calistoga Llc | PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS |
-
2014
- 2014-06-13 SI SI201430672T patent/SI3008053T1/en unknown
- 2014-06-13 WO PCT/US2014/042392 patent/WO2014201409A1/en active Application Filing
- 2014-06-13 EP EP14738957.1A patent/EP3008053B1/en active Active
- 2014-06-13 NZ NZ714710A patent/NZ714710A/en not_active IP Right Cessation
- 2014-06-13 PL PL14738957T patent/PL3008053T3/pl unknown
- 2014-06-13 JP JP2015563142A patent/JP6030783B2/ja active Active
- 2014-06-13 KR KR1020157035901A patent/KR101709436B1/ko active IP Right Grant
- 2014-06-13 AU AU2014277950A patent/AU2014277950B2/en active Active
- 2014-06-13 TR TR2018/06822T patent/TR201806822T4/tr unknown
- 2014-06-13 EA EA201592182A patent/EA028319B1/ru not_active IP Right Cessation
- 2014-06-13 ES ES14738957.1T patent/ES2667173T3/es active Active
- 2014-06-13 MX MX2015017192A patent/MX347988B/es active IP Right Grant
- 2014-06-13 PT PT147389571T patent/PT3008053T/pt unknown
- 2014-06-13 BR BR112015031475A patent/BR112015031475A2/pt not_active IP Right Cessation
- 2014-06-13 AR ARP140102277A patent/AR096621A1/es unknown
- 2014-06-13 SG SG11201509910YA patent/SG11201509910YA/en unknown
- 2014-06-13 CN CN201480033119.7A patent/CN105308034B/zh active Active
- 2014-06-13 TW TW103120507A patent/TWI644909B/zh active
- 2014-06-13 CA CA2915129A patent/CA2915129C/en active Active
- 2014-06-13 US US14/304,539 patent/US9221795B2/en active Active
- 2014-06-16 UY UY0001035617A patent/UY35617A/es not_active Application Discontinuation
- 2014-07-31 NO NO14832802A patent/NO2994608T3/no unknown
-
2015
- 2015-10-21 US US14/919,261 patent/US20160039793A1/en not_active Abandoned
- 2015-11-19 IL IL242677A patent/IL242677B/en not_active IP Right Cessation
-
2016
- 2016-03-11 AU AU2016201584A patent/AU2016201584B2/en not_active Ceased
- 2016-07-27 HK HK16108969.2A patent/HK1220968A1/zh unknown
- 2016-09-09 HK HK16110710.0A patent/HK1223911A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| UY35242A (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| UY35243A (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| DOP2017000151A (es) | Derivados de quinazolina utilizados para tratar el vih | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| DOP2016000299A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1 | |
| DOP2015000158A (es) | Inhibidores de prmt5 y sus usos | |
| ECSP16016726A (es) | Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih | |
| NZ726608A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| NI201700029A (es) | Compuestos y composiciones como inhibidores de quinasa raf. | |
| UY35663A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| CR20120418A (es) | Inhibidores de virus flaviviridae | |
| NZ726360A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| UY36170A (es) | Compuestos de dihidroisoquinolinona sustituida | |
| DOP2019000140A (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih | |
| NZ726638A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
| CR20170496A (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
| CR20160600A (es) | Quinolizione derivados como inhibidores pi3k | |
| SV2016005310A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| EA201791396A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
| EA201791397A1 (ru) | СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
| SV2016005317A (es) | Derivados de pirrolidina -2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1 | |
| CR20160532A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20211206 |